↓ Skip to main content

Current management and novel agents for malignant melanoma

Overview of attention for article published in Journal of Hematology & Oncology, February 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
67 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Current management and novel agents for malignant melanoma
Published in
Journal of Hematology & Oncology, February 2012
DOI 10.1186/1756-8722-5-3
Pubmed ID
Authors

Byung Lee, Nikhil Mukhi, Delong Liu

Abstract

Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 67 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 22%
Student > Ph. D. Student 9 13%
Researcher 9 13%
Student > Postgraduate 9 13%
Student > Master 7 10%
Other 10 15%
Unknown 8 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 22 33%
Medicine and Dentistry 21 31%
Biochemistry, Genetics and Molecular Biology 5 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Nursing and Health Professions 1 1%
Other 4 6%
Unknown 10 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 May 2021.
All research outputs
#5,873,829
of 21,044,876 outputs
Outputs from Journal of Hematology & Oncology
#350
of 1,067 outputs
Outputs of similar age
#37,986
of 138,978 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 1 outputs
Altmetric has tracked 21,044,876 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,067 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 138,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them